公开(公告)号：US20090305975A1

公开(公告)日：2009-12-10

申请号：US12226491

申请日：2007-04-16

申请人： Guang Yang ,  Ningsheng Shao ,  Yaping Gao ,  Yu Liu ,  Jie Dong ,  Shaohua Li ,  Chuan Liu ,  Beifen Shen ,  Ming Fan

发明人： Guang Yang ,  Ningsheng Shao ,  Yaping Gao ,  Yu Liu ,  Jie Dong ,  Shaohua Li ,  Chuan Liu ,  Beifen Shen ,  Ming Fan

IPC分类号： A61K38/16 ,  C07K14/31

CPC分类号： A61K38/164

摘要： Disclosed herein is the use of TRAP per se as an active ingredient for the manufacture of a medicament for the treatment of Staphylococcus aureus infection. An exogenous TRAP (native TRAP or recombinant TRAP) per se can effectively inhibit the production of Staphylococcus aureus exotoxins, thereby reducing the pathogenicity of Staphylococcus aureus. In addition, a medicament including TRAP also stimulates the production of corresponding antibodies in human body at the time when it is used to treat Staphylococcus aureus infections, and these antibodies can further inhibit the production of Staphylococcus aureus exotoxins. Such double actions increase the effects of medicament and provide a novel medicament action mode. Moreover, since TRAP functions merely to the toxicity of bacteria but does not affect the growth of bacteria, it cannot make bacteria readily develop drug resistance, and also effective to drug resistant Staphylococcus aureus. Moreover, no homologous sequence of the TRAP proteins is found in human genome, so that the medicaments of TRAP cannot cause human immunologic diseases.

摘要翻译： 本文公开了TRAP本身作为生产用于治疗金黄色葡萄球菌感染的药物的活性成分的用途。 外源TRAP（天然TRAP或重组TRAP）本身可以有效抑制金黄色葡萄球菌外毒素的产生，从而降低金黄色葡萄球菌的致病性。 此外，包含TRAP的药物在用于治疗金黄色葡萄球菌感染时也刺激人体中相应抗体的产生，并且这些抗体可以进一步抑制金黄色葡萄球菌外毒素的产生。 这种双重作用增加了药物的作用并提供了新的药物作用模式。 此外，由于TRAP仅仅对细菌的毒性起作用，而不影响细菌的生长，所以不能使细菌容易产生耐药性，并且对耐金黄色葡萄球菌也是有效的。 此外，在人类基因组中没有发现TRAP蛋白的同源序列，因此TRAP的药物不能引起人类免疫学疾病。